Adoptive Cell Therapy Using TCR

Adoptive Cell Therapy Using TCR-T Engineered Lymphocytes

Adoptive cell therapy, specifically TCR-T engineered lymphocytes against cancers, has emerged as a cutting-edge strategy in our therapeutic arsenal. In this process, T cells are taken from a patient, genetically engineered to express specific T Cell Receptors (TCRs) that can identify and bind to cancer cells, and then reintroduced into the patient’s body. 

Phase I/II study of adoptive cell therapy using TCR-T engineered lymphocytes against cancers expressing NYESO1 antigen

NY-ESO-1 - New York Esophageal Squamous Cell Carcinoma 1
NCT05296564 : Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes
Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Our innovation

ESO Project Team

Clinical Team

Scientific Collaboration

Bone Marrow Transplantation

Skip to content